CDK inhibitors are now becoming a main focus in RA (Selicyclib and CYCC-065).Rheumatoid arthritis drug market will reach $38.5bn in 2017
Rheumatoid Arthritis (RA): World Drug Market 2013-2023
Publish date :April 2013
Pages :120 pages
Monday 3 June 2013, Amsterdam
A new report predicts the world rheumatoid arthritis (RA) drug market will generate revenue of $38.5bn in 2017. That forecast and others appear in Rheumatoid Arthritis (RA): World Drug Market 2013-2023, published in April 2013.
According to our new study, the overall market for RA drugs will expand during the first half of the forecast period, although with declining annual growth. That revenue expansion is limited by the patent expiry of the leading NSAID, Celebrex, as well as increasing competition and market saturation. Also, the world RA medicines market will have negative growth from 2018 to 2023, as a result of patent expiry of the leading biologic drugs and competition from biosimilars (follow-on biologics).
Jennifer Taylor, a pharmaceutical industry analyst, said: “The strengths of the RA drug market stem from the high profile of the disease, which requires long term drug treatment, generating high volumes of sales. Also, variability in response rates among patients means that the market can support a high number of products. The market will also be supported by a well stocked R&D pipeline. However, patent protection for many of the leading biologic drugs is expected to expire during our forecast period. Changes in legislation around the world, including the US, mean that biosimilars will be approved for marketing. Competition from biosimilars poses a threat to this sector, especially as revenue from biologic drugs currently forms 87.5% of the total RA drug market.”
This report shows revenue forecasts to 2023 at world market, submarket, product and national level. It forecasts these world-level submarkets:
Biologics (biological drugs)
For the non-biologics submarket, there are further revenue breakdowns to 2023:
Others agents (grouped, including novel DMARDs and corticosteroids).
That investigation also predicts revenues of leading brands in the rheumatoid arthritis drugs market, including Celebrex, Arcoxia, Remicade, Humira and Enbrel. Research, data and analyses cover activities of Abbott Laboratories (AbbVie), Roche, Pfizer, Johnson & Johnson, Amgen and other pharmaceutical companies.
That new study also discusses R&D and commercial developments, shows research interviews and predicts overall revenues to 2023 in leading national markets. The work analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC countries).
Rheumatoid Arthritis (RA): World Drug Market 2013-2023 therefore adds to range of analytical reports on industries and markets in healthcare.
By 2017 CYCC will have 70-80 million outstanding shares with dilution... be trading under $1 again...
and will do its 3rd reverse split again... They are just like XOMA dilute heavy , reverse split and science will
fail.... Why do you think Big Pharma stays away from CYCC ..... They dont want to waste there money on
a probably failed drug imo... Now you are on the RA band wagon... Now, you are reaching for anything now... You talk about a 60 bagger ? I apologize but you are out of your mind..
"Their science will fail" ? Can you be more specific ? How will it fail? 20% of the SEAMLESS pilot are already living 2-3 years out (unprecedented in this population). SAP doubled survival in RMDS as a single agent (unprecedented in this population). CYCC is in partnering discussions with big pharma now (per earnings CC). Impressive responses in SAP/ SEL phase 1 studies in BRCA deficient advanced solid Tumors ( unprecedented in this population). Selicyclib in investigator sponsored study to confirm encouraging preclinical data suggesting SEL's effective modulation of inflammatory factors involved in R/A. (This is only one of many autoimmune /inflammatory diseases that SEL could address.) Investigator sponsored CLL phase 2 studies are evaluating SAP's combination potential with two other agents. This study is based on preclinical data suggesting SAP as an ideal combination agent with multiple other regimens due to its oral administration, unique spectrum and low toxicity. This unique spectrum was highlighted and confirmed in the recent RMDS phase 2 data in which SAP achieved responses refractory to HMA's similar to what is seen in the front line. Company has "enough cash beyond completion of SEAMLESS".